Skip to main content

AcelRx Pharmaceuticals Value Stock - Dividend - Research Selection

AcelRx Pharmaceuticals

ISIN: US00444T1007, WKN: A1H64B

Market price date: 21.09.2020
Market price: 1,81 USD




AcelRx Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 28-02-2020
Cash flow
Net operating cash flow -51.180.000
Capital Expenditures -3.470.000
Free cash flow -54.650.000
Balance sheet
Total Equity -41.418.000
Liabilities & Shareholders equity 91.356.000
Income statement
Net income -53.240.000
Eps (diluted) -0,670
Diluted shares outstanding 79.184.000
Net sales/revenue 2.289.000

Fundamental ratios calculated on: 21-09-2020

Ratios
Key figures 21-09-2020
Cash flow
P/C -2,80
   
P/FC -2,62
Balance sheet
ROI-58,28
ROE-45,34
Income statement
P/E-2,70
Div. Yield0,00%
P/B-3,46
P/S62,61


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolACRX
Market Capitalization143.323.040,00 USD
CountryUnited States
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internethttp://www.acelrx.com


Description of the company

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, http://www.acelrx.com